Log In
Print this Print this

PF-03446962, PF-3446962

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHuman mAb against activin receptor-like kinase 1 (ACVRL1; ALK1; HHT2)
Molecular Target Activin receptor-like kinase 1 (ACVRL1) (ALK1) (HHT2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationLiver cancer
Indication DetailsSecond-line treatment for hepatocellular carcinoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today